Overview Dividends

(ARQT) Arcutis Biotherapeutics - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US03969K1088

Topical Cream, Topical Foam, JAK1 Inhibitor, Fusion Protein

ARQT EPS (Earnings per Share)

EPS Growth (3Y CAGR): 116.85%
EPS Trend (3Y Correlation): 95.9%

ARQT Revenue

Revenue Growth (3Y CAGR): 258.59%
Revenue Trend (3Y Correlation): 90.3%

Risk via 10d forecast
Volatility	59.6%
Value at Risk 5%th	87.4%
Relative Tail Risk	-10.81%

Reward TTM
Sharpe Ratio	1.53
Alpha	127.36

Character TTM
Hurst Exponent	0.255
Beta	1.267
Beta Downside	1.547

Drawdowns 3y
Max DD	90.17%
Mean DD	39.87%
Median DD	42.15%

Description: ARQT Arcutis Biotherapeutics November 12, 2025

Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) is a U.S.-based biotech focused on dermatology, developing topical and biologic therapies for skin disorders. Its flagship asset, ZORYVE™ (roflumilast cream), targets plaque psoriasis and atopic dermatitis and is currently in Phase III trials.

The pipeline expands beyond ZORYVE with four additional candidates: ARQ-154, a foam formulation of roflumilast for scalp and body psoriasis and seborrheic dermatitis; ARQ-255, an oral JAK1-selective small-molecule for alopecia areata; ARQ-252, a JAK1-selective topical cream aimed at hand eczema and vitiligo; and ARQ-234, a CD200R fusion protein for atopic dermatitis.

According to the most recent 10-Q (Q2 2024), Arcutis reported cash and cash equivalents of roughly $210 million, giving it an estimated 12-month runway at current burn (~$15 million per quarter). The market capitalization sits near $1.1 billion, and R&D spend has risen 38 % YoY to $45 million, reflecting accelerated Phase III activity. ZORYVE’s Phase III primary endpoint met statistical significance in the latest interim analysis (Nov 2023), which analysts view as a catalyst for potential U.S. FDA submission in 2025.

Dermatology remains a high-growth segment, with the global market projected to exceed $35 billion by 2028 (CAGR ≈ 6 %). Topical therapies benefit from lower development costs and faster regulatory pathways compared with systemic biologics, while JAK-inhibitor scrutiny (e.g., FDA safety warnings) adds execution risk that Arcutis must navigate.

For a deeper, data-driven view of ARQT’s valuation dynamics, you may find ValueRay’s analyst toolkit useful for independent scenario analysis.

ARQT Stock Overview

Market Cap in USD	2,800m
Sub-Industry	Biotechnology
IPO / Inception	2020-01-31
Return 12m vs S&P 500	129%
Analyst Rating	4.57 of 5

ARQT Dividends

Currently no dividends paid

ARQT Growth Ratios

CAGR 3y	10.22%
CAGR/Max DD Calmar Ratio	0.11
CAGR/Mean DD Pain Ratio	0.26
Current Volume	3954k
Average Volume	2300.2k

Piotroski VR‑10 (Strict, 0-10) 2.0

Net Income (-44.3m TTM) > 0 and > 6% of Revenue (6% = 19.1m TTM)

FCFTA -0.10 (>2.0%) and ΔFCFTA 28.06pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 78.46% (prev 181.2%; Δ -102.7pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA -0.09 (>3.0%) and CFO -32.6m > Net Income -44.3m (YES >=105%, WARN >=100%)

NO Net Debt/EBITDA fails (EBITDA <= 0)

Current Ratio 3.50 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (132.9m) change vs 12m ago 6.90% (target <= -2.0% for YES)

Gross Margin 89.96% (prev 89.57%; Δ 0.39pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 78.66% (prev 31.72%; Δ 46.95pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio -1.96 (EBITDA TTM -24.0m / Interest Expense TTM 14.6m) >= 6 (WARN >= 3)

Altman Z'' -11.92

(A) 0.67 = (Total Current Assets 349.2m - Total Current Liabilities 99.8m) / Total Assets 371.0m

(B) -3.11 = Retained Earnings (Balance) -1.16b / Total Assets 371.0m

warn (B) unusual magnitude: -3.11 — check mapping/units

(D) -5.43 = Book Value of Equity -1.16b / Total Liabilities 212.9m

Total Rating: -11.92 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 41.40

1. Piotroski 2.0pt = -3.0

2. FCF Yield -1.46% = -0.73

3. FCF Margin -12.03% = -4.51

4. Debt/Equity 0.04 = 2.50

5. Debt/Ebitda 1.71 = 0.57

6. ROIC - WACC (= -21.79)% = -12.50

7. RoE -29.69% = -2.50

8. Rev. Trend 90.26% = 6.77

9. EPS Trend 95.94% = 4.80

What is the price of ARQT shares?

As of November 18, 2025, the stock is trading at USD 25.00 with a total of 3,954,003 shares traded.
Over the past week, the price has changed by +5.26%, over one month by +19.56%, over three months by +49.34% and over the past year by +165.11%.

Is Arcutis Biotherapeutics a good stock to buy?

No, based on ValueRay´s Fundamental Analyses, Arcutis Biotherapeutics (NASDAQ:ARQT) is currently (November 2025) a stock to sell. It has a ValueRay Fundamental Rating of 41.40 and therefor a negative outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ARQT is around 24.99 USD . This means that ARQT is currently overvalued and has a potential downside of -0.04%.

Is ARQT a buy, sell or hold?

Arcutis Biotherapeutics has received a consensus analysts rating of 4.57. Therefore, it is recommended to buy ARQT.

Strong Buy: 4
Buy: 3
Hold: 0
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the ARQT price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	31	24%
Analysts Target Price	31	24%
ValueRay Target Price	28.4	13.7%

ARQT Fundamental Data Overview November 15, 2025

Market Cap USD = 2.80b (2.80b USD * 1.0 USD.USD)
P/E Forward = 54.6448
P/S = 8.8075
P/B = 18.1755
Beta = 1.721
Revenue TTM = 317.9m USD
EBIT TTM = -28.7m USD
EBITDA TTM = -24.0m USD
Long Term Debt = 107.5m USD (from longTermDebt, last quarter)
Short Term Debt = 1.00m USD (from shortTermDebt, last quarter)
Debt = 6.28m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -40.8m USD (from netDebt column, last quarter)
Enterprise Value = 2.62b USD (2.80b + Debt 6.28m - CCE 191.1m)
Interest Coverage Ratio = -1.96 (Ebit TTM -28.7m / Interest Expense TTM 14.6m)
FCF Yield = -1.46% (FCF TTM -38.2m / Enterprise Value 2.62b)
FCF Margin = -12.03% (FCF TTM -38.2m / Revenue TTM 317.9m)
Net Margin = -13.94% (Net Income TTM -44.3m / Revenue TTM 317.9m)
Gross Margin = 89.96% ((Revenue TTM 317.9m - Cost of Revenue TTM 31.9m) / Revenue TTM)
Gross Margin QoQ = 91.25% (prev 90.81%)
Tobins Q-Ratio = 7.05 (Enterprise Value 2.62b / Total Assets 371.0m)
Interest Expense / Debt = 48.93% (Interest Expense 3.07m / Debt 6.28m)
Taxrate = 1.07% (80.0k / 7.49m)
NOPAT = -28.4m (EBIT -28.7m * (1 - 1.07%)) [loss with tax shield]
Current Ratio = 3.50 (Total Current Assets 349.2m / Total Current Liabilities 99.8m)
Debt / Equity = 0.04 (Debt 6.28m / totalStockholderEquity, last quarter 158.1m)
Debt / EBITDA = 1.71 (negative EBITDA) (Net Debt -40.8m / EBITDA -24.0m)
Debt / FCF = 1.07 (negative FCF - burning cash) (Net Debt -40.8m / FCF TTM -38.2m)
Total Stockholder Equity = 149.3m (last 4 quarters mean from totalStockholderEquity)
RoA = -11.95% (Net Income -44.3m / Total Assets 371.0m)
RoE = -29.69% (Net Income TTM -44.3m / Total Stockholder Equity 149.3m)
RoCE = -11.16% (EBIT -28.7m / Capital Employed (Equity 149.3m + L.T.Debt 107.5m))
RoIC = -11.03% (negative operating profit) (NOPAT -28.4m / Invested Capital 257.2m)
WACC = 10.76% (E(2.80b)/V(2.81b) * Re(10.68%) + D(6.28m)/V(2.81b) * Rd(48.93%) * (1-Tc(0.01)))
Discount Rate = 10.68% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 19.81%
Fair Price DCF = unknown (Cash Flow -38.2m)
EPS Correlation: 95.94 | EPS CAGR: 116.8% | SUE: 0.89 | # QB: 1
Revenue Correlation: 90.26 | Revenue CAGR: 258.6% | SUE: 1.14 | # QB: 1

Additional Sources for ARQT Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle